In the U.S., atrial fibrillation (AF), a heart condition that causes an irregular heartbeat in the upper chambers of the ...

Athletes who undergo ablation to treat their irregular heartbeat caused by atrial fibrillation (AF) experience greater ...

CardioFocus has treated the first patients in an investigational trial of OptiShot, its pulsed field ablation (PFA) system ...

CardioFocus announced that investigators completed the first series of treatments in a study of its OptiShot pulsed-field ...

A combination of Imbruvica and venetoclax showed significantly prolonged progression-free survival in patients with untreated ...

In patients with atrial fibrillation, a resting heart rate of 80 bpm or higher is associated with increased risk for mortality.

Jaypirca showed superior progression-free survival and lower discontinuation rates versus standard treatments in patients ...

The global Ablation Technology Market is projected to reach USD 13.61 Billion by 2031 from USD 5.78 Billion in 2024, at a CAGR of 9.34% from 2024 to 2031.Luton, Bedfordshire, United Kingdom, Dec. 18, ...

In the U.S., atrial fibrillation (AF), a heart condition that causes an irregular heartbeat in the upper chambers of the heart, affects up to one in three people in their lifetime. Significant ...

CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac arrhythmias, today ...